SPRAVATO® • BREA, CA

A monitored treatment pathway
for treatment-resistant depression.

Spravato® is intranasal esketamine. Cortex Psychiatry evaluates candidacy and provides treatment in a structured clinical setting when medically appropriate.

Abstract illustration representing monitored Spravato treatment

HOW THE PROGRAM WORKS

Evaluation, administration, monitoring.

01

Psychiatric assessment

We review diagnosis, prior antidepressant treatment, medical history, medications, substance-use risk, blood pressure considerations, and treatment goals.

02

Supervised treatment

Spravato® is self-administered under healthcare supervision in a certified treatment setting according to prescribing and REMS requirements.

03

Observation and follow-up

Patients are monitored after dosing, including for sedation, dissociation, and blood-pressure changes, and are discharged only when clinically appropriate.

TREATMENT PLANNING

Spravato® is one part of a broader psychiatric plan.

Candidacy depends on diagnosis, prior treatment, medical and psychiatric history, safety considerations, patient preference, and applicable coverage requirements. Treatment recommendations are made after physician evaluation.